Overview
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well ^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
American College of Radiology Imaging NetworkCollaborators:
National Cancer Institute (NCI)Radiation Therapy Oncology Group
Treatments:
CarboplatinDocetaxel
Etoposide
Fluorodeoxyglucose F18
Paclitaxel
Vinblastine
Vinorelbine
Criteria
DISEASE CHARACTERISTICS:- Histologically confirmed non-small cell lung cancer (NSCLC)
- Clinical stage IIB or III disease
- No small cell carcinoma
- No stage IV disease*
- No diffuse bronchoalveolar subtype
- No planned definitive surgical resection NOTE: *Patients with evidence of stage
IV disease by positron emission tomography are eligible if the evidence cannot be
confirmed by other means AND the physician still plans to proceed with definitive
chemoradiation
- Planning treatment with definitive chemoradiotherapy
- May be treated on another Radiation Therapy Oncology Group protocol (except phase
I studies) OR with conventional concurrent NSCLC chemoradiotherapy
- Radiotherapy ≥ 60 Gy AND chemotherapy to include concurrent platinum-based
therapy
- No brain metastases by head CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Medically suitable for early concurrent chemoradiotherapy (radiotherapy dose ≥ 60 Gy)
- Able to tolerate positron emission tomography imaging
- No poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL)
- No other malignancy within the past 3 years except basal cell or squamous cell skin
cancer or carcinoma in situ
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study
participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No anticipated use of adjuvant biologic therapy beyond 14 weeks after the completion
of radiotherapy
Chemotherapy
- See Disease Characteristics
- No anticipated use of adjuvant chemotherapy beyond 14 weeks after the completion of
radiotherapy
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- No prior thoracic radiotherapy
- No concurrent intensity-modulated radiotherapy
Surgery
- See Disease Characteristics